<DOC>
	<DOCNO>NCT01037231</DOCNO>
	<brief_summary>The purpose study determine Oxalobacter formigenes effective lower urinary oxalate level patient primary hyperoxaluria .</brief_summary>
	<brief_title>Phase 2/3 Oxabact Study</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<criteria>1 . Signed informed consent ( applicable age subject ) 2 . Male female subject ≥ 2 year age 3 . A mean urinary oxalate excretion &gt; 1.0 mmol/1.73m2/day eligible urine collection perform screen . 4 . A diagnosis PH I PH II one following : 1 . Liver biopsy confirmation deficient liver specific peroxisomal alanineglyoxylate aminotransferase , ( AGT ) mislocalization AGT peroxisomes mitochondrion ( PH I ) deficient glyoxylate reductase/hydroxypyruvate reductase ( GRHPR ) activity ( PH II ) 2 . Homozygosity compound heterozygosity know mutation causative gene PH I PH II . 3 . Increased glycolate excretion PH I increase Lglycerate excretion PH II . 5 . Subjects receive pyridoxine must receive stable dose least 3 month prior entry study must remain stable dose study . Subjects receive pyridoxine study entry must willing refrain initiate pyridoxine study participation . 6 . Renal function define estimate GFR ≥ 40 ml/min normalize 1.73m2 body surface area , creatinine clearance ≥ 40 ml/min normalize 1.73m2 body surface area . 7 . Inability collect two complete 24hour urine sample . Each urine collection evaluate completeness base urine acceptance criterion outline section 11.1 . 8 . Subjects diagnose PH I pyridoxine naïve . 9 . Subjects undergone transplantation ( solid organ bone marrow ) . 10 . The existence secondary hyperoxaluria , e.g . chronic gastrointestinal disease cystic fibrosis , chronic inflammatory bowel disease shortbowel syndrome . 11 . Current systemic ( oral , IM , IV ) antibiotic use receive systemic antibiotic within 14 day study enrolment . 12 . History recurrent infection require &gt; 2 course systemic antibiotic past 6 month , chronic antimicrobial suppression . 13 . Subjects require immune suppressive therapy ( include prednisone &gt; 10mg daily 2 week ) . 14 . Current treatment separate ascorbic acid preparation . Ascorbic acid 250mg/day component multivitamin formulation exclude . 15 . Known hypersensitivity esomeprazol ( ingredient medicine ) , proton pump inhibitor medicine . ( Nexium contraindication ) 16 . Concomitant treatment atazanavir . ( Nexium contraindication ) 17 . Pregnancy . 18 . Women childbearing potential use adequate contraceptive precaution . Sexually active female , unless surgically sterile least 2 year postmenopausal , must use highly effective contraception ( include oral , transdermal , injectable , implanted contraceptive , IUD , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose OxabactTM must agree continue use precaution clinical study . 19 . Presence medical condition Principal Investigator consider likely make subject susceptible adverse effect study treatment unable follow study procedure . Note : Subjects correctional facility asylums subject mentally handicap include study . 20 . Participation study investigational product , biologic , device , agent within 30 day prior randomization willing forego form investigational treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hyperoxaluria</keyword>
	<keyword>oxalate</keyword>
	<keyword>PH</keyword>
</DOC>